Register for OBR daily




To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

ADXS $7.28 1.6701 +29.77%
RDUS $37.49 5.4600 +17.05%
CRIS $1.33 0.1600 +13.68%
MGNX $38.77 4.2400 +12.28%
FPRX $27.34 1.4500 +5.60%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

CALA $23.07 -4.8600 -17.40%
GILD $92.98 -15.4750 -14.27%
PTLA $28.86 -1.8500 -6.02%
EPZM $18.80 -1.1800 -5.91%
GLYC $8.15 -0.4900 -5.67%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | Next > | Last >>

Cancer Genetics, Inc. Announces Launch of Targeted Next Generation Sequencing Based Panel for Chronic Lymphocytic Leukemia, Focus::CLL

(NASDAQ) Dec 8, 2014 - Cancer Genetics, Inc. announced today it has been licensed by the Clinical Laboratory Improvement Amendments (CLIA) to perform Focus::CLL(TM), the company's unique next-generation sequencing (NGS)-based panel for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
read article 



'60 Minutes' Cancer Doctor's Revolutionary Idea: Taking Big Data Seriously

(Forbes) Dec 8, 2014 - Soon-Shiong’s characterization of cancer as fundamentally a problem with cell death rather than cell growth isn’t new or radical.
read article 



BlackBerry Plans Medical Tool For Its Passport Smartphone

(Wall Street Journal) Dec 7, 2014 - BlackBerry Ltd. said it plans to launch, early in the new year, a mobile diagnostic tool for its Passport device to allow doctors to securely access cancer patients’ medical data from any location.
read article (paid subscription required) 



Advaxis Announces FDA Acceptance of Its Investigational New Drug Application to Commence Clinical Trials of ADXS-PSA in Combination With Merck's KEYTRUDA(R) (pembrolizumab) For Prostate Cancer

(NASDAQ) Dec 8, 2014 - Advaxis, Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to conduct a Phase 1/2 clinical study to evaluate the combination of ADXS-PSA (ADXS31-142) with KEYTRUDA(R) (pembrolizumab), marketed by Merck & Co., Inc., in patients with previously treated, metastatic castration-resistant prostate cancer (mCRPC).
read article 



Agios Announces Celgene Decision to Extend Discovery Phase of Global Strategic Collaboration to April 2016

(Agios) Dec 8, 2014 - Agios Pharmaceuticals, Inc. today announced that Celgene Corporation has elected to extend the period of its exclusivity for an additional year to April 2016 under the global strategic collaboration agreement.
read corporate press release 



ASH: The Celgene Show, This Time Through Partners

(CNBC) Dec 8, 2014 - Celgene's partnering strategy, which started to take shape in 2008 and has accelerated in recent years, is starting to bear fruit; many of the most-watched stocks out of ASH fall under its umbrella, from Agios Pharmaceuticals to Acceleron Pharma.
read article 



Immunotherapy Confidence (and Audience) Abundant at ASH T-Cell Talk

(Xconomy) Dec 8, 2014 - With cancer immunotherapy tallying impressive patient results and new drug approvals, people in the field are confident about expanding its scope.
read article 



The 7 Most Important Drug-Stock Lessons From This Weekend's Blood Cancer Meeting

(TheStreet) Dec 8, 2014 - Here's what I learned about biotech and drug stocks after covering the American Society of Hematology annual meeting.
read article 



New Study Identifies First Gene Associated With Familial Glioma

(Baylor College of Medicine) Dec 7, 2014 – An international consortium of researchers led by Baylor College of Medicine has identified for the first time a gene associated with familial glioma (brain tumors that appear in two or more members of the same family) providing new support that certain people may be genetically predisposed to the disease.
read press release 



Older Breast Cancer Patients Still Get Radiation Despite Limited Benefit

(Duke Medicine) Dec 8, 2014 - Women over the age of 70 who have certain early-stage breast cancers overwhelmingly receive radiation therapy despite published evidence that the treatment has limited benefit, researchers at Duke Medicine report.
read press release 



SABCS: Spotlight on Ovarian Suppression in Breast Cancer

(Medpage Today) Dec 8, 2014 - The role of ovarian suppression atop standard anti-estrogen therapy for younger breast cancer survivors will take focus as the San Antonio Breast Cancer Symposium gets underway this week.
read article (free registration required) 



Genetic Errors Linked to Aging Underlie Leukemia That Develops After Cancer Treatment

(WUSTL) Dec 8, 2014 - For a small percentage of cancer patients, treatment aimed at curing the disease leads to a form of leukemia with a poor prognosis.
read press release 



Immune Checkpoint Tx Takes Down Ca

(Medpage Today/The Gupta Guide) Dec 8, 2014 - Treatment with an immune checkpoint inhibitor led to consistent responses across multiple types of cancer, particularly in patients with suppressed immune systems that appeared to be "reinvigorated" by the therapy, investigators reported.
read article (free registration required) 



Agios Reports Positive Phase 1 Data in Healthy Volunteers for AG-348, a First-in-Class Investigational Medicine That Targets the Underlying Cause of Pyruvate Kinase (PK) Deficiency

(Agios) Dec 8, 2014 - Agios Pharmaceuticals, Inc. today presented the first clinical data from its Phase 1 single (SAD) and multiple ascending dose (MAD) clinical trials of AG-348 in healthy volunteers.
read corporate press release 



Galena Biopharma Presents GALE-401 (Anagrelide Controlled Release) Clinical Trial Data at the 56th American Society of Hematology (ASH) Annual Meeting & Exposition

(CNNMoney) Dec 8, 2014 - Phase 1 results demonstrate GALE-401 reduces platelet counts with tolerable safety profile; preliminary Phase 2 clinical trial data show promising platelet response with top-line data to be presented mid-year 2015.
read article 



Narrow Subset of Cells Is Responsible For Metastasis in Multiple Myeloma, Study Finds

(Dana-Farber) Dec 7, 2014 - Although it is among the most highly metastatic of all cancers, multiple myeloma is driven to spread by only a subset of the myeloma cells within a patient’s body, researchers at Dana-Farber Cancer Institute have found.
read press release 



Treatment For Relapsed Multiple Myeloma Patients Guided by FoundationOne® Heme Results in Promising Clinical Activity

(TheStreet) Dec 8, 2014 – Foundation Medicine, Inc. today announced new data demonstrating that its comprehensive genomic profile, FoundationOne® Heme, identified genomic alterations in patients with heavily pre-treated multiple myeloma that informed treatment with trametinib, an FDA-approved targeted therapeutic agent.
read article 



Stem Cell Transplant Without Radiation or Chemotherapy Pre-Treatment Shows Promise For Rare Bone Marrow Failure

(Dana-Farber) Dec 7, 2014 - Trial reports transplant success in a rare bone marrow failure syndrome, following conditioning with immunosuppressive drugs alone.
read press release 



Common Genetic Variations May Contribute to Treatment-Related Cognitive Problems in Children With Leukemia

(Dana-Farber) Dec 9, 2014 - Common variations in four genes related to brain inflammation or cells' response to damage from oxidation may contribute to the problems with memory, learning and other cognitive functions seen in children treated for acute lymphoblastic leukemia (ALL), according to a study led by researchers from Boston Children’s Hospital, The Children's Hospital at Montefiore, and Dana-Farber/Boston Children's Cancer and Blood Disorders Center.
read press release 



Treat Young Adults With ALL as Children For Better Outcomes

(Medscape Medical News) Dec 8, 2014 - Adolescents and young adults with acute lymphocytic leukemia (ALL) who are treated with pediatric regimens have significantly better in event-free and overall survival, new research shows.
read article (free registration required) 



Experimental Gene Therapy Successful in Certain Lymphomas and Leukemia

(MD Anderson) Dec 8, 2014 - Study results of CD19-directed chimeric antigen receptor (CAR) therapy using the Sleeping Beauty non-viral transduction system to modify T cells has demonstrated further promise in patients with advanced hematologic malignancies.
read press release 



Seattle Genetics Highlights Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations in Frontline and Salvage Hodgkin Lymphoma at ASH Annual Meeting

(Seattle Genetics) Dec 8, 2014 - Seattle Genetics, Inc. today highlighted multiple ADCETRIS (brentuximab vedotin) data presentations in frontline and salvage Hodgkin lymphoma (HL) at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in San Francisco, CA, December 6-9, 2014.
read corporate press release 



Sunesis Announces Presentation of Positive Updated Results From Ongoing MD Anderson-Sponsored Trial of Vosaroxin in AML and High-Risk MDS at ASH Annual Meeting

(StreetInsider) Dec 8, 2014 - Sunesis Pharmaceuticals, Inc. today announced the presentation of updated results from an ongoing Phase 1b/2 University of Texas MD Anderson Cancer Center-sponsored trial of vosaroxin in combination with decitabine in older patients with previously untreated acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
read article 



ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib From Phase 2 Pace Clinical Trial

(MarketWatch) Dec 8, 2014 - ARIAD Pharmaceuticals, Inc. today announced long-term follow up from its pivotal Phase 2 trial of Iclusig® (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
read article 



Gilead Presents Follow-Up Data From Zydelig Registrational Studies in Patients With Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma

(Wall Street Online) Dec 8, 2014 - Gilead Sciences, Inc. today announced long-term follow-up results from the registration studies further describing the duration of response, progression-free survival (PFS) and safety profile for Zydelig® (idelalisib) in relapsed patients with chronic lymphocytic leukemia (CLL) and two types of indolent non-Hodgkin lymphoma (iNHL).
read article